Evaluation of a rapid screening test for rifampicin resistance in re-treatment tuberculosis patients in the Eastern Cape

South African Medical Journal

Volumn 97, Issue 9, 2007, Pages 858-863

  Albert, H ^a,d   Trollip, A P ^a   Seaman, T ^a,e   Abrahams, C ^a   Mole, R J ^a   Jordaan, A ^b   Victor, T ^b   Hoosain, E ^c  

^a NEW SOMERSET HOSPITAL   (South Africa)

^b STELLENBOSCH UNIVERSITY   (South Africa)

^c Nelson Mandela Bay Municipality   (South Africa)

^d Foundation for Innovative New Diagnostics (FIND)   (South Africa)

^e UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; RIFAMPICIN;

ACID FAST BACTERIUM; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIOPHAGE TYPING; BACTERIUM CULTURE; BACTERIUM ISOLATE; BACTERIUM ISOLATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DRUG TREATMENT FAILURE; HUMAN; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; OUTCOME ASSESSMENT; PROGNOSIS; SCREENING TEST; SENSITIVITY AND SPECIFICITY; SOUTH AFRICA; SPUTUM ANALYSIS; TUBERCULOSIS CONTROL;

ANTIBIOTICS, ANTITUBERCULAR; BACTERIOPHAGE TYPING; DRUG RESISTANCE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; PREDICTIVE VALUE OF TESTS; RETREATMENT; RIFAMPIN; SOUTH AFRICA; SPUTUM; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 34848821622     PISSN: 02569574     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. World Health Organization. Global Tuberculosis Control. Surveillance, Planning, Financing. 2004. Geneva: WHO, 2004.
2. Bamford L, Loveday M, Verkuijl S. Tuberculosis. In: Ijumba P, Day C, Ntuli A, eds. South African Health Review 2003/04. Durban: Health Systems Trust, 2004.
3. World Health Organization. Anti-tuberculosis Drug Resistance in the World. Report No. 3. The WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance 1999-2002. Geneva: WHO, 2004.
4. Farmer P, Bayona J, Becerra M, et al. The dilemma of MDR-TB in the global era. Int J Tuberc Lung Dis 1998; 2: 869-876.
5. Department of Health. DOTS-Plus for Standardised Management of Multidrug-Resistant Tuberculosis in South Africa. Policy Guidelines. Pretoria: DOH, 2004.
6. Espinal MA, Kim SJ, Suarez PG, et al. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries, JAMA 2000; 283: 2537-2545.
7. Wilson SM. Method to detect bacteria. PCT Patent WO97/022713. 1997.
8. Wilson SM, Al-Suwaldi Z, McNerney R, Porter J, Drobniewski F. Evaluation of a new rapid bacteriophage-based method for the drug susceptibility testing of Mycobacterium tuberculosis. Nature Medicine 1997; 3: 465-468.
9. Albert H, Heydenrych A, Brookes R, et al. Performance of a rapid phage-based test, FASTPlaqueTB, to diagnose pulmonary tuberculosis from sputum specimens in South Africa. Int J Tuberc Lung Dis 2002; 6: 529-537.
10. Marei AM, El-Behedy EM, Mohtady HA, Afify AF. Evaluation of a rapid bacteriophage-based method for the detection of Mycobacterium tuberculosis in clinical samples. J Med Microbiol 2003; 52: 331-335.
11. Muzaffar R, Batool S, Aziz F, Naqvi A, Rizvi A. Evaluation of the FASTPlaque TB assay for direct detection of Mycobacterium tuberculosis in sputum specimens. Int J Tuberc Lung Dis 2002; 6: 635-640.
12. Wilson, D, Maartens G. Identifying sputum smear-negative tuberculosis in HIV infected adults using a bacteriophage assay. First South African AIDS Conference, Durban, South Africa, August 2003 (Abstract).
13. Albert H, Trollip A, Seaman T, Mole RJ. Simple, phage-based (FASTPlaque) technology to determine rifampicin resistance of Mycobacterium tuberculosis directly from sputum. Int J Tuberc Lung Dis 2004; 8: 1114-1119.
14. Albert H, Heydenrych A, Mole R, Trollip AP, Blumberg L. Evaluation of FASTPlaqueTB-RIF, a rapid, manual test for the determination of rifampicin resistance from M. tuberculosis cultures, Int J Tuberc Lung Dis 2001; 5: 906-911.
15. Kisa P, Albay A, Bedir O, Baylan O, Doganci L. Evaluation of FASTPlaqueTB-RIF for determination of rifampicin resistance in Mycobacterium tuberculosis complex isolates. Int J Tuberc Lung Dis 2003; 7: 284-288.
16. Department of Health. The South African Tuberculosis Control Programme Practical Guidelines. Pretoria: DOH, 1996.
17. Biotec Laboratories Ltd. FASTPlaque-Response product insert. For performance evaluation only. Version 180903. Biotec Laboratories Ltd., Ipswich, UK, 2003.
18. Enarson DA, Rieder HL, Arnadotiir T, Trebucq A. Management of Tuberculosis. A Guide for Low Income Countries. Paris: International Union Against Tuberculosis and Lung Disease, 2000.
19. Kent PT, Kubica GP. Public Health Mycobacteriology. A Guide for the Level III Laboratory. Atlanta, GA: Centers for Disease Control, 1985.
20. Victor TC, Jordaan AM, van Rie A, et al. Detection of mutations in drug resistance genes of Mycobacterium tuberculosis by a dot-blot hybridisation strategy. Tuberc Lung Dis 1999; 79: 343-348.
21. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977; 33: 159-174.
22. Teixeira L, Perkins MD, Johnson JL, et al. Infection and disease among household contacts of patients with multidrug-resistant tuberculosis. Int J Tuberc Lung DIS 2001; 5: 321-328.
23. Mole RJ, Trollip AP, Seaman T, Abrabams C, Albert H. Improved contamination control using a new antimicroblal supplement developed for rapid phage-based rifampicin susceptibility testing. Int J Tuberc Lung Dis 2005; 9: Suppl 1, S271.
24. Chavez Pachas AM, Blank R, Smith Fawzi MC, Bayona J, Becerra MC, Mitnick CD. Identifying early treatment failure on category I therapy for pulmonary tuberculosis in Lima Cuidad, Peru. Int J Tuberc Lung Dis 2004; 8(1): 52-58.